Skip to content

Study · Not a test of the peptide alone · 2022

2 results

Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer's mouse model.

Chu X, Hou Y, Meng Q, Croteau DL, Wei Y, De S, Becker KG, Bohr VA

Frontiers in aging neuroscience15 Sept 2022Cited by 24 (Europe PMC)

PMID36185477 (opens in a new tab)PMCIDPMC9520302 (opens in a new tab)DOI10.3389/fnagi.2022.993615 (opens in a new tab)PepBankPUB-36185477
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Alzheimer's disease (AD) is the most common neurodegenerative disease. Growing evidence suggests an important role for gut dysbiosis and gut microbiota-host interactions in aging and neurodegeneration. Our previous works have demonstrated that supplementation with the nicotinamide adenine dinucleotide (NAD+) precursor, nicotinamide riboside (NR), reduced the brain features of AD, including neuroinflammation, deoxyribonucleic acid (DNA) damage, synaptic dysfunction, and cognitive impairment. However, the impact of NR administration on the intestinal microbiota of AD remains unknown. In this study, we investigated the relationship between gut microbiota and NR treatment in APP/PS1 transgenic (AD) mice. Compared with wild type (WT) mice, the gut microbiota diversity in AD mice was lower and the microbiota composition and enterotype were significantly different. Moreover, there were gender differences in gut microbiome between female and male AD mice. After supplementation with NR for 8 weeks, the decreased diversity and perturbated microbial compositions were normalized in AD mice. This included the species Oscillospira, Butyricicoccus, Desulfovibrio, Bifidobacterium, Olsenella, Adlercreutzia, Bacteroides, Akkermansia, and Lactobacillus. Our results indicate an interplay between NR and host-microbiota in APP/PS1 mice, suggesting that the effect of NR on gut dysbiosis may be an important component in its therapeutic functions in AD.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  1. 01AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, NR supplementation normalized decreased gut microbiota diversity.

    In plain wordsIn mice with Alzheimer's disease, NR supplementation normalized reduced gut microbiota diversity.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseGut microbiota diversity
    Study

    mousen: not reported in source

    APP/PS1 transgenic Alzheimer's disease mice
    Outcome group
    Gut microbiota · Gastrointestinal

    Source sentences

    Summary
    After supplementation with NR for 8 weeks, the decreased diversity and perturbated microbial compositions were normalized in AD mice.
    1 context sentence
    Summary · context
    In this study, we investigated the relationship between gut microbiota and NR treatment in APP/PS1 transgenic (AD) mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  2. 02AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, NR supplementation normalized disturbed microbial composition, including the listed bacterial genera.

    In plain wordsIn mice with Alzheimer's disease, NR supplementation normalized disturbed gut microbial composition.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    MixedGut microbiota composition
    Study

    mousen: not reported in source

    APP/PS1 transgenic Alzheimer's disease mice
    Outcome group
    Gut microbiota · Gastrointestinal

    Source sentences

    Summary
    After supplementation with NR for 8 weeks, the decreased diversity and perturbated microbial compositions were normalized in AD mice.
    2 context sentences
    Summary · context
    This included the species Oscillospira, Butyricicoccus, Desulfovibrio, Bifidobacterium, Olsenella, Adlercreutzia, Bacteroides, Akkermansia, and Lactobacillus.
    Summary · context
    In this study, we investigated the relationship between gut microbiota and NR treatment in APP/PS1 transgenic (AD) mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.